Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Eribulin mesylate by Eisai for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval
Eribulin mesylate is under clinical development by Eisai and currently in Phase III for Metastatic Transitional (Urothelial) Tract Cancer. According...